Aggressive breast cancer may be sensitive to drugs attacking their waste disposal

Share this article:
Aggressive breast cancer may be sensitive to drugs attacking their waste disposal
Aggressive breast cancer may be sensitive to drugs attacking their waste disposal

Triple-negative breast cancers may be vulnerable to drugs that attack the proteasome. The proteasome is the cellular structure that disposes the waste of the cell by breaking down damaged or unneeded proteins.

Triple-negative breast cancers lack the three major therapeutic markers for breast cancer, which are the estrogen, progesterone, and HER2 receptors. These types of breast cancers are very aggressive and difficult to treat. They mostly affect younger women and have the worst prognosis of all breast cancers. After treatment, these breast cancers are prone to relapse and metastasis.

This research team, led by Judy Lieberman, PhD, of Boston Children's Hospital in Massachusetts, did a genome-wide screen of basal-like triple-negative breast cancers to identify their genetic dependencies, which then indicates potential drug targets. Their screen found that basal-like breast cancers, and not other subtypes of breast cancer, are often addicted to the proteasome and MCL-1. Basal-like breast cancers were found to be sensitive to proteasome inhibitors.

By selectively turning genes off throughout the genomes of triple-negative tumor cells in vitro, the research team found that these cells absolutely require active proteasomes in order to live. When the proteasomes are turned off, the cells die. Inhibiting proteasomes in mice with tumors from basal-like cell lines inhibited the growth of the tumors and their metastasis.

These data, published in Cancer Cell (2013; doi: 10.1016/j.ccr.2013.07.008), suggest that triple-negative breast cancers may respond to treatment with drugs similar to bortezomib, which is a proteasome inhibitor that has revolutionized the care of patients with the blood cancer multiple myeloma. However, bortezomib does not penetrate tumors well, so next-generation proteasome inhibitors should be investigated for the basal-like subtype of triple-negative breast cancer. Other genes that basal-like triple-negative breast cancer depends on include glycolytic enzyme genes and potassium-sodium exchange transporters, and these may also be potential targets.
Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Biomarker for aggressive, basal-like breast cancer identified

A biomarker strongly linked to basal-like breast cancer has been identified.

Tumor suppressor mutations alone do not explain deadly cancer

Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.